MOTS-c + NAD+ — claim review
Heavily marketed in the longevity / biohacker space as a 'mitochondrial regeneration' protocol. Both compounds have interesting mechanistic biology; neither has Phase 3 longevity outcome data. The combination has zero human trial support.
What people claim
- “Mitochondrial regeneration reverses ageing”
- “Boosts NAD+ levels to youthful range”
- “Treats long COVID and chronic fatigue”
- “Replaces hours of exercise”
What the evidence shows
MOTS-c is a 16-amino-acid mitochondrial-derived peptide with preclinical metabolic and exercise-mimetic data. There are no published human Phase 3 trials for longevity, long COVID, or any clinical outcome.
Oral NMN / NR raise blood NAD+ precursor levels modestly in human studies; meaningful clinical-outcome benefit (longevity, healthspan, disease prevention) is not yet demonstrated. IV NAD+ delivers high systemic doses; longevity outcomes are unproven and infusion-clinic marketing far exceeds the evidence base.
UK regulatory framing
MOTS-c is unlicensed. NMN / NR are sold as food supplements. IV NAD+ is typically administered in private 'longevity clinics'; it is not a UK NHS treatment for any indication and is unlicensed for longevity claims.
Safer alternatives
- Regular aerobic + resistance exercise — the only intervention with strong evidence for healthspan extension.
- Mediterranean-style diet, sleep optimisation, smoking cessation.
- Routine NHS cancer screening and cardiovascular risk review.
Frequently asked questions
- Does MOTS-c + NAD+ slow ageing?
- No randomised human trial demonstrates that. Both compounds have intriguing mechanistic biology. Neither has Phase 3 longevity-outcome trial data. The combination has zero trial evidence.
- Is NAD+ infusion the same as oral NMN / NR?
- No. Oral NMN and NR are precursors that may modestly raise NAD+ tissue levels. IV NAD+ delivers high systemic doses with their own safety considerations. Neither has proven longevity outcomes.
- Is MOTS-c legal in the UK?
- MOTS-c is not a licensed UK medicine. Sale with human-use claims engages UK regulatory rules. See /legal/mots-c-uk-law.
- Are these safe to combine?
- Combination safety is uncharacterised. Both have unknown long-term effects. NAD+ pathway disruption may interact with chemotherapy mechanisms — discuss with a clinician if you have any cancer history or risk.
- Why is this combination marketed together?
- Both have 'mitochondrial' marketing positioning that appeals to longevity audiences. The story sells; the trial evidence does not yet support it.